Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Glioblastoma: The Current State of Affairs

No Improvement With Temozolomide Dose Intensification or Treatment Prolongation

Treatment at Recurrence

Glioblastoma: Improving Outcomes

No Survival Benefit of Adding Bevacizumab to Standard of Care, Despite Improved PFS

Immunotherapy: No Established Improvement of Outcome in Glioblastoma

Promise of Personalized Treatment Strategies Has Not Yet Delivered for Glioblastoma and Other Gliomas

EGFR and Glioblastoma: Still a Relevant Target?

Trials of EGFR Inhibition in Recurrent Glioblastoma Invariably Failed

Why Did We Fail, Despite the Prominent Role of EGFR Signalling in Glioblastoma?

BRAF Mutations in Glioma: An Actionable Target

Ongoing Inhibitor Studies With EGFR Inhibitors

Nanocell, EGFR, and Doxorubicin: EnGeneIC Delivery Vehicle (EDV)

Current Approaches to Targeted Therapies: Ligand‑Compound Constructs

Antibody-Drug Conjugates: A Novel and Clinically Successful Approach

Antibody-Drug Conjugates: Proof of Concept and MOA

Depatux-M (ABT-414): ADC of ABT-806 With MMAF Attached

Phase 1 M12-356: Depatux-M in EGFR-Amplified GBM

Depatux-M: Toxicity Profile

Depatux-M: Toxicity Profile: Response and Duration of Study in Phase 1 Expansion Cohorts on EGFR-Amplified Recurrent GBM

Depatux-M: Clinical Development Program: INTELLANCE1 and INTELLANCE2 Pivotal Studies

INTELLANCE 2 Phase 2 Trial Design M14-483/EORTC-1410-BTG

Long-Term Follow-Up: Treatment and Time Since TMZ

Long-Term Follow-Up: Treatment and Methylation Status

Depatux-M: Current Status

Rindopepimut: EGFRvIII Vaccination

Adoptive T-Cell Therapy With CAR-Redirected T Lymphocytes

CAR-T Cells: A Treatment Alternative in Glioma?

Conclusion: Ongoing Approaches Targeting EGFR

Abbreviations

Abbreviations (cont)